In yesterday’s Wall Street session, Nektar Therapeutics (NASDAQ:NKTR) shares traded at $0.81, down -1.77% from the previous session.
As of this writing, 8 analysts cover Nektar Therapeutics (NASDAQ:NKTR). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $0.60, we find $1.75. Given the previous closing price of $0.82, this indicates a potential upside of 113.41 percent. NKTR stock price is now 32.88% away from the 50-day moving average and -51.25% away from the 200-day moving average. The market capitalization of the company currently stands at $172.36M.
There are 6 analysts who have given it a hold rating, whereas 0 have given it a buy rating. Brokers who have rated the stock have averaged $2.35 as their price target over the next twelve months.
With the price target reduced from $1.50 to $1, Jefferies Upgraded its rating from Underperform to Hold for Nektar Therapeutics (NASDAQ: NKTR).
In other news, WHITFIELD ROY A, Director sold 30,000 shares of the company’s stock on Jun 14. The stock was sold for $17,100 at an average price of $0.57. Upon completion of the transaction, the Director now directly owns 216,250 shares in the company, valued at $0.18 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 16, President & CEO ROBIN HOWARD W sold 20,361 shares of the business’s stock. A total of $14,660 was realized by selling the stock at an average price of $0.72. This leaves the insider owning 939,797 shares of the company worth $0.76 million. Insiders disposed of 325,608 shares of company stock worth roughly $0.26 million over the past 1 year. A total of 1.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in NKTR stock. A new stake in Nektar Therapeutics shares was purchased by MONACO ASSET MANAGEMENT SAM during the first quarter worth $7,492,000. SIO CAPITAL MANAGEMENT, LLC invested $5,659,000 in shares of NKTR during the first quarter. In the first quarter, ACUITAS INVESTMENTS, LLC acquired a new stake in Nektar Therapeutics valued at approximately $584,000. QUBE RESEARCH & TECHNOLOGIES LTD acquired a new stake in NKTR for approximately $306,000. MOLONEY SECURITIES ASSET MANAGEMENT, LLC purchased a new stake in NKTR valued at around $287,000 in the second quarter. In total, there are 258 active investors with 94.80% ownership of the company’s stock.
Tuesday morning saw Nektar Therapeutics (NASDAQ: NKTR) opened at $0.8390. During the past 12 months, Nektar Therapeutics has had a low of $0.51 and a high of $5.18. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 8.70, and a quick ratio of 8.30. The fifty day moving average price for NKTR is $0.6130 and a two-hundred day moving average price translates $1.6453 for the stock.
The latest earnings results from Nektar Therapeutics (NASDAQ: NKTR) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.27, beating analysts’ expectations of -$0.28 by 0.01. This compares to -$0.85 EPS in the same period last year. The company reported revenue of $20.5 million for the quarter, compared to $21.59 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -5.03 percent. For the current quarter, analysts expect NKTR to generate $21.48M in revenue.
